The metabolic benefit of genetic deletion/inhibition of MGAT2 was evidenced in mice models with increased energy expenditure, decreased hepatic triglyceride levels, resistance to developing insulin resistance and obesity, and increased postprandial GLP-1 concentrations in response to a high-fat diet [79,80]. The gene discussed is GCG; the disease is obesity disorder.